In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: Carbon analogs of (-)-cytisine

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 12, 2005, Pages 2974-2979

  Coe, Jotham W ^a   Vetelino, Michael G ^a   Bashore, Crystal G ^a   Wirtz, Michael C ^a   Brooks, Paige R ^a   Arnold, Eric P ^a   Lebel, Lorraine A ^a   Fox, Carol B ^a   Sands, Steven B ^a   Davis, Thomas I ^a   Schulz, David W ^a   Rollema, Hans ^a   Tingley III, F David ^a   O'Neill, Brian T ^a  

^a PFIZER INC   (United States)

Author keywords

4 2 Nicotinic receptor; Alkaloid; nAChR; Partial agonist; Smoking cessation

Indexed keywords

ALPHA4BETA2 NICOTINIC RECEPTOR; CARBON; CYTISINE; DIPYRONE; NICOTINIC AGENT; NICOTINIC RECEPTOR; PARTIAL AGONIST; PHENYL GROUP; UNCLASSIFIED DRUG; ALKALOID; AZOCINE DERIVATIVE; DOPAMINE; NICOTINIC RECEPTOR ALPHA4BETA2; QUINOLIZINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYCLIZATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SYNTHESIS; HECK REACTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; NONHUMAN; RAT; SMOKING CESSATION; ANIMAL; CHEMISTRY; DRUG EFFECT; METABOLISM; NUCLEUS ACCUMBENS; STRUCTURE ACTIVITY RELATION;

ALKALOIDS; ANIMALS; AZOCINES; CARBON; DOPAMINE; NICOTINIC AGONISTS; NUCLEUS ACCUMBENS; QUINOLIZINES; RATS; RECEPTORS, NICOTINIC; SMOKING CESSATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 19944400775     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.04.036     Document Type: Article

References (67)

1. Sir Walter Raleigh brought tobacco from Virginia in 1584
2. A.L. Taylor, and D.W. Bettcher Bull. World Health Organ. 78 2000 920
3. World Health Organization. The World Health Report. Geneva, 2002
4. M. Ezzati, and A.D. Lopez Tob Control. 13 2004 388
5. R. Doll, R. Peto, K. Wheatley, R. Gray, and I. Sutherland BMJ 309 1994 901
6. R. Doll, R. Peto, J. Boreham, and I. Sutherland BMJ 328 2004 1519
7. J.E. Rose Ann. Rev. Med. 47 1996 493
8. R.D. Hurt, D.P. Sachs, E.D. Glover, K.P. Offord, J.A. Johnston, L.C. Dale, M.A. Khayrallah, D.R. Schroeder, P.N. Glover, C.R. Sullivan, I.T. Croghan, and P.M.N. Sullivan Engl. J. Med. 337 1997 1195
9. D. Jorenby Drugs 62 Suppl. 2 2002 25
10. J.F. Cryan, F. Gasparinia, G. van Heekeb, and A. Markou Drug Disc. Today 8 2003 1025
11. R. Peto, S. Darby, H. Deo, P. Silcocks, E. Whitley, and R. Doll BMJ 321 2000 323
12. Coe, J. W.; Brooks, P. R.; Vetelino, M. G.; Wirtz, M. C.; Arnold, E. P.; Sands, S. B.; Davis, T. I.; Lebel, L. A.; Fox, C. B.; Shrikhande, A.; Schaeffer, E.; Rollema, H.; Lu, Y.; Mansbach, R. S.; Chambers, L. K.; Rovetti, C. C.; Schulz, D. W.; Tingley III, F. D.; O'Neill, B. T. J. Med. Chem., 2005, 48, 3474
13. T.P. Carmody J. Psychoactive Drugs 24 1992 131
14. G. Di Chiara Eur. J. Pharmacol. 2375 1999 13
15. R.C. Hogg, and D. Bertrand Curr. Drug Targets-CNS Neurol. Disord. 3 2004 123
16. R.S. Mansbach, L.K. Chambers, and C.C. Rovetti Psychopharmacology 148 2000 234
17. S.S. Watkins, M.P. Epping-Jordan, G.F. Koob, and A. Markou Pharmacol. Biochem. Behav. 62 1999 743
18. M.R. Picciotto, M. Zoli, R. Rimondini, C. Lena, L.M. Marubio, E.M. Pich, K. Fuxe, and J.P. Changeux Nature 391 1998 173
19. J.A. Dani, and M. De Biasi Pharmacol. Biochem. Behav. 70 2001 439
20. A.R. Tapper, S.L. McKinney, R. Nashmi, J. Schwarz, P. Deshpande, C. Labarca, P. Whiteaker, M.J. Marks, A.C. Collins, and H.A. Lester Science 5 2004 1029
21. We have focused on α4β2 and have not performed an exhaustive study of emergent heteromeric permutations that have recently been identified. L.M. Marubio, A.M. Gardier, S. Durier, D. David, R. Klink, M.M. Arroyo-Jimenez, J.M. McIntosh, F. Rossi, N. Champtiaux, M. Zoli, and J.-P. Changeux Eur. J. Neurosci. 17 2003 1329
22. For upper and lower limits for these values see: L.E. Chavez-Noriega, A. Gillespie, K.A. Stauderman, J.H. Crona, B.O. Claeps, K.J. Elliott, R.T. Reid, T.S. Rao, G. Velicelebi, M.M. Harpold, E.C. Johnson, and J. Corey-Naeve Neuropharmacology 39 2000 2543
23. M.E. Nelson, A. Kuryatov, C.H. Choi, Y. Zhou, and J.M. Lindstrom Mol. Pharmacol. 63 2003 332
24. J.R. DiFranza, and R. Wellman J. Nic. Tobacco Res. 7 2005 9 26
25. M.W. Quick, and R.A.M. Lester J. Neurobiol. 53 2002 457
26. J. Littleton Addiction 96 2001 87
27. B.T. Zhu J. Theor. Biol. 181 1996 273
28. C. Cohen, O.E. Bergis, F. Galli, A.W. Lochead, S. Jegham, B. Biton, J. Leonardon, P. Avenet, F. Sgard, F. Besnard, D. Graham, A. Coste, A. Oblin, O. Curet, C. Voltz, A. Gardes, D. Caille, G. Perrault, P. George, P. Soubrie, and B. Scatton J. Pharmacol. Exp. Ther. 306 2003 407
29. K. Fagerstrom Drugs 62 Suppl. 2 2002 1
30. K. Fagerstrom J. Clin. Psychiatry Monograph 18 2003 35
31. Isolation: A. Partheil Arch. Pharm. 232 1894 161
32. Structure determination: H.R. Ing J. Chem. Soc. 1932 2778
33. R.L. Papke, and S.F. Heinemann Mol. Pharmacol. 45 1994 142
34. G. Scharfenberg, S. Benndorf, and G. Kempe Dtsch. Gesundheitsw. 26 1971 463
35. R.B. Barlow, and L.J. McLead Br. J. Pharmacol. 35 1969 161
36. C. Reavill, B. Walther, I.P. Stolerman, and B. Testa Neuropharmacology 29 1990 619
37. J.E. Rose, F.M. Behm, and E.C. Westman Clin. Pharmacol. Ther. 56 1994 86 99
38. J.E. Rose, F.M. Behm, E.C. Westman, E.D. Levin, R.M. Stein, J.D. Lane, and G.V. Ripka Exp. Clin. Psychopharmacol. 6 1998 331
39. O'Neill, B. T. Preparation of pyridone-fused azabicyclic- or (-)-cytisine derivatives for use in addiction therapy. WO9818798, May 7, 1998, U.S. Patent 6,235,734, May 22, 2001, and U.S. Patent 6,630,467, October 7, 2003
40. E. Marriere, J. Rouden, V. Tadino, and M.-C. Lasne Org. Lett. 2 2000 1121
41. O. Nicolotti, C. Canu Boido, F. Sparatore, and A. Carotti Farmaco 57 2002 469
42. C. Canu Boido, A. Carotti, and F. Sparatore Farmaco 58 2003 265
43. B.T. O'Neill, D. Yohannes, M.W. Bundesmann, and E.P. Arnold Org. Lett. 2 2000 4201
44. E. Marriere, J. Rouden, V. Tadino, and M.-C. Lasne Org. Lett. 2 2000 1121
45. C. Botuha, M.S. Galley, and T. Gallagher Org. Biol. Chem. 2 2004 1825
46. B. Danieli, G. Lesma, D. Passarella, A. Sacchetti, A. Silvani, and A. Virdis Org. Lett. 6 2004 493
47. T. Honda, R. Takahashi, and H. Namiki J. Org. Chem. 70 2005 499
48. Although the syntheses of compounds with structures of this type have been reported, their nicotinic activity was not studied. For instance see: K.J. Blackall, D. Hendry, R.J. Pryce, and S.M. Roberts J. Chem. Soc., Perkin Trans. 1 21 1995 2767
49. W.K. Chang, L.A. Walter, and R.I. Taber J. Med. Chem. 14 1971 1011
50. S. Shiotani, T. Kometani, and K. Mitsuhashi Chem. Pharm. Bull. 24 1976 541
51. Coe, J. W. Arylfused azapolycyclic compounds. PCT Int. Appl. WO99 55,680, 1999. U.S. Patent 6,462,035, October 8, 2002, and U.S. Patent 6,706,702, March 16, 2004
52. J.W. Coe Org. Lett. 2 2000 4205
53. W.E. Parham, and C.K. Bradsher Acc. Chem. Res. 15 1982 300
54. V. Snieckus Chem. Rev. 6 1990 879
55. J.W. Coe, K.E. Bianco, B.P. Boscoe, P.R. Brooks, E.D. Cox, and M.G. Vetelino J. Org. Chem. 68 2003 9964
56. R.F. Heck W.G. Dauben Organic Reactions Vol. 27 1982 Wiley New York 345
57. N. Miyaura, and A. Suzuki Chem. Rev. 95 1995 2457
58. C.G. Bashore, I.J. Samardjiev, J. Bordner, and J.W. Coe J. Am. Chem. Soc. 125 2003 3268
59. P.R. Brooks, S. Caron, J.W. Coe, K.K. Ng, R.A. Singer, E. Vazquez, M.G. Vetelino, H.H. Watson Jr., D.C. Whritenour, and M.C. Wirtz Synthesis 2004 1755
60. R.E. Dolle, S.J. Schmidt, and L.I. Kruse J. Chem. Soc., Chem. Commun. 1987 904
61. P.M. Lippiello, and K.G. Fernandes Mol. Pharmacol. 29 1986 448
62. D.J. Anderson, and S.P. Arneric Eur. J. Pharmacol. 253 1994 261 For practical reasons, determination of α4β2 affinity was performed in both rat cortical tissue and hα4β2 transfected HEK (human embryonic kidney) cells
63. R.A. Glennon, and M. Ducat Pharm. Acta. Helv. 74 2000 103
64. W. Stuhmer Methods Enzymol. 207 1992 319
65. A.I. Sacaan, R.T. Reid, E.M. Santori, P. Adams, L.D. Correa, L.S. Mahaffy, L. Bleicher, N.D. Cosford, K.A. Stauderman, I.A. McDonald, T.S. Rao, and G.K. Lloyd J. Pharmacol. Exp. Ther. 280 1997 373
66. Dopamine turnover (%) is the ratio of DOPAC + HVA/DA = (3,4-dihydroxyphenylacetic acid + homovanillic acid/dopamine) = (DOPEC + 3-methoxy-4-hydroxyphenyl acetic acid/DA). Determined in male Sprague Dawley rats, 200-300 g. Doses were chosen based on in vitro data and tolerability as determined from in vivo studies
67. See Refs. 8, 30, and 36 for all experimental details